BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
11/30/2022 - National Advertising Division Finds Certain Perrigo Infant Formula Cost Savings Claims Supported; Recommends Others be Modified or Discontinued
New York, NY – November 30, 2022 – The National Advertising Division (NAD) determined that Perrigo Company plc provided a reasonable basis for certain cost savings claims for its store brand hypoallergenic infant formula but recommended that other challenged claims be modified or discontinued.
-
11/30/2022 - National Advertising Division Refers Comparative Advertising Claims made by Zscaler to Federal Trade Commission for Further Review
New York, NY – November 30, 2022 – The National Advertising Division (NAD) referred Zscaler to the Federal Trade Commission (FTC) after the company failed to respond substantively to a challenge into claims made for its Zero Trust Exchange Platform. NAD recommended that Zscaler discontinue claims about various privacy protection attributes and benefits of its Zero Trust Exchange platform versus the technical capabilities of Prisma Access, the platform of challenger Palo Alto Networks.
-
11/22/2022 - National Advertising Division Finds Certain HEPA Claims for Shark Air Purifiers Supported; SharkNinja Appeals Recommendation to Modify or Discontinue Others
New York, NY – November 22, 2022 – In a challenge brought by Dyson, Inc., the National Advertising Division (NAD) determined that SharkNinja Operating LLC provided a reasonable basis for claims that its Shark Air Purifier 4 meets or even exceeds HEPA standards but recommended that Shark discontinue these same claims for its Air Purifier 6.
-
11/22/2022 - NAD Finds Certain Environmental Benefit Claims for ABA’s “Every Bottle Back” Initiative Supported; ABA Appeals Recommendation to Modify Other Claims
New York, NY – November 22, 2022 – The National Advertising Division (NAD) determined that the American Beverage Association (ABA) provided a reasonable basis for certain environmental benefit claims related to its Every Bottle Back program, designed to encourage and increase beverage container recycling in the U.S.
-
11/21/2022 - National Advertising Division Recommends Cash App Financial Services Platform Discontinue or Modify Megan Thee Stallion Video About Investing
New York, NY – November 21, 2022 – The National Advertising Division (NAD) recommended that Cash App discontinue or modify its video commercial with Megan Thee Stallion telling consumers they can invest as little as a dollar, followed by her adding a gold bar to a stack of gold bars and saying that “with my knowledge and your hustle, you’ll have your own empire in no time.”
-
11/15/2022 - National Advertising Division Recommends T-Mobile Modify or Discontinue Certain TV Commercial Claims for Magenta Max Wireless Service Plan
New York, NY – November 15, 2022 – The National Advertising Division (NAD) recommended that T-Mobile US, Inc. modify or discontinue certain claims for its Magenta Max mobile wireless service plan. The claims at issue, which appeared in two T-Mobile television commercials (the “Please Listen” ad and the “Cumpleanos” ad), were challenged by competitor AT&T Services, Inc.
-
11/14/2022 - Genexa Appeals NAD Recommendation to Discontinue or Modify Pediatrician Preference and Ingredient Claims for OTC Kids’ Pain & Fever Medicine
New York, NY – Nov. 14, 2022 – The National Advertising Division (NAD) recommended that Genexa Inc. discontinue certain pediatrician preference claims and ingredient claims for its over the counter (OTC) Kids’ Pain & Fever medicine. Genexa will appeal NAD’s decision. The challenged claims appeared on the advertiser’s website, in social media posts, on physical point-of-sale displays, and in digital video advertising.
-
11/08/2022 - National Advertising Division Recommends P&G Discontinue or Modify Comparative Advertising Commercials for Puffs Ultra Soft Tissues vs. Kleenex
New York, NY – November 8, 2022 – Acting on a challenge brought by Kimberly-Clark Corporation, the National Advertising Division (NAD) recommended that The Procter & Gamble Company (P&G) discontinue two commercials for Puffs Ultra Soft Tissues or modify them to avoid conveying a misleading message about the softness, comfort, or safety of Kleenex tissues and that Puff’s tissues have visible quilt-like puffing.
-
11/07/2022 - National Advertising Division Recommends Comcast Modify or Discontinue Xfinity Mobile vs. T-Mobile Comparative Savings Claims
New York, NY – November 7, 2022 – The National Advertising Division (NAD) analyzed comparative savings claims made by Comcast Cable about its Xfinity Mobile Wireless service plan. NAD recommended that Comcast either discontinue a claim that Xfinity Mobile is 30% less than T-Mobile or modify the advertising to clearly and conspicuously disclose the T-Mobile plan that is the basis of comparison and the material differences between the plans.
-
11/02/2022 - National Advertising Review Board Finds Sanofi’s “#1 Doctor Recommended Ingredient” Claims for Zantac 360° Unsubstantiated
New York, NY – November 2, 2022 – A panel of the National Advertising Review Board (NARB), the appellate advertising law body of BBB National Programs, recommended that Sanofi Consumer Healthcare not use claims that Zantac 360° contains, or that famotidine is, “the #1 Doctor Recommended ingredient” or “the #1 Doctor Recommended ingredient among H2 Blockers.”